Three Continents, One Gene: DNA Detectives Track Down Nerve Disorder Cause

Gene mutation responsible of inherited ataxia found through sophisticated genetic analysis of Asian, European & American families

Newswise ANN ARBOR, Mich. A global hunt for the cause of a crippling inherited nerve disorder has found its target. The discovery opens the door for better diagnosis and treatment of this particular disease but also for better understanding of why nerves in the brains movement-controlling center die, and how new DNA-mapping techniques can find the causes of other diseases that run in families.

In a new paper in the Annals of Neurology, a team from Taiwan, France and the University of Michigan Health System report that mutations in the gene KCND3 were found in six families in Asia, Europe and the United States that have been haunted by the same form of a disease called spinocerebellar ataxia or SCA. The disease causes progressive loss of balance, muscle control and ability to walk.

The new paper finds the disease gene in a region of chromosome 1 where a Dutch group had previously shown linkage with a form of SCA called SCA19, and the Taiwanese group on the new paper had shown similar linkage in a family for a form of the disease that was then called SCA22.

The Dutch group has just published results in the same issue of the journal, zeroing in on the same gene as the U-M/Taiwanese/French groups.

The gene governs the production of a protein that allows nerve cells to talk to one another through the flow of potassium. Pinpointing its role as a cause of ataxia will now allow more people with ataxia to learn the exact cause of their disease, give a very specific target for new treatments, and perhaps allow the families to stop the disease from affecting future generations.

But the findings also have significance beyond ataxia. The researchers also show that when KCND3 is mutated, it causes not only poor communication between nerve cells in the cerebellum but also the death of those cells. Its information that could aid research on other neurological disorders involving balance and movement.

Margit Burmeister, Ph.D., the U-M geneticist who helped lead the work, notes that the gene could not have been found without a great deal of DNA detective work and the cooperation of the families who volunteered to let researchers map all the DNA of multiple members of their family tree.

We combined traditional genetic linkage analysis in families with inherited diseases with whole exome sequencing of an individuals DNA, allowing us to narrow down and ultimately identify the mutation, she says. This new type of approach has already resulted in many new gene identifications, and will bring in many more.

U-M neurologist Vikram Shakkottai, M.D., Ph.D., an ataxia specialist and co-author on the paper, notes that the new genetic information will help patients find out the specific cause of their disease a reassuring thing in itself.

Read more:
Three Continents, One Gene: DNA Detectives Track Down Nerve Disorder Cause

Source:
http://www.longevitymedicine.tv/feed/

Rasheda Ali, Daughter of Legendary Muhammad Ali and Advisory Board Member of BrainStorm, Visits Company Laboratories …

NEW YORK & PETACH TIKVAH, Israel–(BUSINESS WIRE)–

BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies and CNS therapeutics, announced that Rasheda Ali Walsh, daughter of the legendary Muhammad Ali, visited the Companys laboratories as well as its cleanrooms at Hadassah Medical Center, where she received a briefing on the companys clinical trial conducted there. Ms. Ali Walsh, an internationally known advocate for promoting research and awareness of neurodegenerative diseases, is a member of the Advisory Board of BrainStorm.

BrainStorms President, Mr. Chaim Lebovits, and CEO Dr. Adrian Harel accompanied Ms. Ali Walsh for a meeting with Prof. Dimitrios Karussis, Principal Investigator of the Companys ongoing Phase I/II clinical trial at Hadassah, and Prof. Tamir Ben-Hur, Head of the Neurology Department. The group discussed the latest innovative treatments for neurodegenerative diseases and BrainStorms leading role in this area.

Having heard so much about the recent positive interim safety report and the outstanding progress being made by BrainStorm at Hadassah, I felt the need to actually meet the team in person, commented Ms. Ali. The amazing work being done here gives a ray of hope to patients and families worldwide that autologous stem cell transplants may be the answer theyve been waiting for to overcome neurodegenerative diseases.

According to Dr. Adrian Harel, BrainStorms CEO, The support and encouragement by world-renowned individuals like Rasheda Ali is important for increasing awareness of the need for a cure for debilitating neurodegenerative diseases. We are hopeful that this awareness will lead to more widespread efforts by governments and health organizations worldwide to fund research in this area and provide assistance to patients and their families.

About BrainStorm Cell Therapeutics, Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of adult stem cell therapeutic products derived from autologous bone marrow cells and intended for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel-Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

Safe Harbor Statement Statements in this announcement other than historical data and information constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as may, should, would, could, will, expect, likely, believe, plan, estimate, predict, potential, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm’s limited operating history, history of losses; minimal working capital, dependence on its license to Ramot’s technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorms forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or managements beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Read this article:
Rasheda Ali, Daughter of Legendary Muhammad Ali and Advisory Board Member of BrainStorm, Visits Company Laboratories …

Source:
http://www.longevitymedicine.tv/feed/

ReNeuron Group plc – Stroke Trial Update

ReNeuron Group (Berlin: RQE.BE – news) plc

(“ReNeuron” or the “Company”)

ReNeuron receives DSMB clearance to progress to higher dose in stem cell clinical trial in stroke patients

First (OTC BB: FSTC.OB – news) patient treated in this higher dose cohort

Guildford, UK, 14 August 2012: ReNeuron Group plc (AIM: RENE) today provides an update on progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. In this open label, dose-ranging Phase I safety study, taking place in Scotland, ReNeuron’s ReN001 stem cell therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition.

The Company is pleased to report that the independent Data Safety Monitoring Board (DSMB) for the clinical trial has recommended that the trial advances to the evaluation of a higher dose of ReN001 in the third of four dose cohorts to be treated in the study. In arriving at this recommendation, the DSMB reviewed safety data from the first two dose cohorts of six patients treated with ReN001. Of these patients, two are through 18 month follow-up, one is through 12 month follow-up, one is through 9 month follow-up, one is through 6 month follow-up and one is through three month follow-up. No cell-related adverse events or adverse immune-related responses have been reported in any of the patients treated to date.

The Company is also pleased to report that the first patient in this third dose cohort of three patients has now been successfully treated with ReN001 and discharged from hospital with no acute safety issues arising.

The primary aim of the PISCES study is to test the safety and tolerability of the treatment in ascending doses of the ReN001 cells, in patients with moderate to severe functional neurological impairments resulting from their stroke. The secondary aim of the study is to evaluate efficacy measures for the design of future clinical trials with ReN001, including imaging measures as well as a number of tests of sensory, motor and cognitive functions.

In June of this year, interim data from the PISCES study from the first five patients treated was presented by the Glasgow clinical team at Glasgow at the 10th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Yokohama, Japan (EUREX: FMJP.EX – news) . Reductions in neurological impairment and spasticity were observed in all five patients compared with their stable pre-treatment baseline performance and these improvements were sustained in longer term follow-up.

The PISCES study is the world’s first fully regulated clinical trial of a neural stem cell therapy for disabled stroke patients. Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world. The trial is being conducted in Scotland at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board.

Continue reading here:
ReNeuron Group plc – Stroke Trial Update

Source:
http://www.longevitymedicine.tv/feed/

Autism advocate Temple Grandin in Arkansas

(ROBYN BECK/AFP/Getty Images)

LITTLE ROCK, Ark. (KTHV) – A national autism advocate is speaking in Little Rock about autism, what it is, and how to address it in your family.

Temple Grandin, is a source of inspiration for those with autism and their families. Grandin is an autism activist who was diagnosed with the disorder at age 2. She’s also one of the nation’s foremost experts on the treatment of livestock and says she remembers what it was like to grow up autistic.

“When I was little kid I couldn’t talk. I can remember the frustrations of not being able to talk. I had extremely good early education and early intervention. I can’t emphasize enough develop the child’s strength,” says Grandin.

Grandin, who designed curved chutes and other systems for cattle handling, worries other autistic children won’t get those opportunities. That’s the message she spoke about Monday in Little Rock.

“If you have a 2 or 3 year old child who’s not talking worst thing you can do is do nothing. Then you got the kids who are quirky and different and I’m very upset that these schools have taken the hands-on classes out. All the art and woodshop and cooking and sewing and welding, because those classes teach practical problem solving,” Grandin says.

Clarke Delp knows all too well how autism can affect families. She says Grandin has offered her help with her own autistic child.

“At the age of 6 he was diagnosed with autism. Part of me was a little relieved because I knew what I was dealing with then. Because for 6 years not knowing what I was dealing with was a struggle,” says Delp.

Now, her autistic son Warren is 10-years old. She says Grandinhelped her cope with his disorder.

“She has made sure that her life has not been defined by autism. She has accomplished such incredible things. Autism certainly comes with great challenges, but it doesn’t necessarily mean that you cannot live a fulfilling life, a successful independent life,” says Delp. “She gives me hope, she gives most of the parents, all the parents I know hope that their child can be successful as she is.”

See the original post here:
Autism advocate Temple Grandin in Arkansas

Source:
http://www.longevitymedicine.tv/feed/

Higher Parkinson’s Risk Linked to Certain Solvents

Increased risks for Parkinsons disease have been linked to some solvents. Parkinsons disease is a progressive, degenerative central nervous system disorder that typically affects motor skills and speech, among other functions and, while not fatal, complications can be deadly. The cause is unknown and there is no cure.

Samuel M. Goldman, M.D., M.P.H., of The Parkinsons Institute in Sunnyvale, California, and colleagues, conducted a so-called discordant twin pair design study involving 99 pairs of twins. The study was conducted to determine if exposure to specific solvents is linked to increased risks for Parkinsons disease. Participant interviews involved task-specific and lifetime occupation and hobby questions, said Medical Xpress. The study was published in the Annals of Neurology.

The researchers found that exposure to trichloroethylene (TCE) was associated with a significantly increased risk of Parkinsons disease and saw a trend for significance for exposure to the chemicals perchloroethylene (PERC) and carbon tetrachloride (CCl4). Although the present work focused on occupational exposures, solvents are ubiquitous in the environment, and this is particularly true for those implicated in this studyTCE, PERC, and CCl4, the authors wrote, according to Medical Xpress. Our findings require replication in other populations with well-characterized exposures, but the potential public health implications are considerable, the team authored.

Weve also written that over the past several years, the agricultural pesticide paraquat has been linked to Parkinsons, posing a risk to agricultural workers who toil in fields where the pesticide is sprayed, as well as to people living near the fields.

Other research revealed that people exposed at their workplaces to ziram, maneb, and paraquat tripled their risk of Parkinsons; workplace exposure to both ziram and paraquat nearly doubled Parkinsons risk; and people who worked with either paraquat or the pesticide rotenone were 2.5 times likelier to develop Parkinsons disease.

Another study found that some medications, notably the amphetamines Benzedrine or Dexedrine, used to treat attention deficit hyperactivity disorder (ADHD) and help patients achieve more defined focus and increase clarity and awareness, could also place those patients at risk for Parkinsons disease.

We recently wrote that another study found an association with glyphosate, the active ingredient in Monsatos Roundup, and Parkinsons disease and Parkinsons-related brain disorders. According to a report from the Organic Authority, Roundup is the best-selling pesticide in the world and is the companion chemical application to many of the companys genetically modified seeds including corn, soy, canola and cotton.

According to Digital Journal, this is just the latest study to find a link between glyphosate and Parkinsons-like disorders. For example, a 2011 report published in the journal Parkinsonism Related Disorders, detailed the case of a 44-year-old women with Parkinsons-like symptoms after sustaining long-term chemical exposure to glyphosate for three years as a worker in a chemical factory.

Read more here:
Higher Parkinson’s Risk Linked to Certain Solvents

Source:
http://www.longevitymedicine.tv/feed/

Speaker offers insights into Parkinson’s

FAIRMONT – It wasn’t until celebrities such as Michael J. Fox and Muhammad Ali announced they had Parkinson’s Disease that the public began to learn more about this life-altering disease.

While not a terminal illness, Parkinson’s does affect the quality of life for those diagnosed.

“About one in 100 people over the age of 60 are diagnosed with Parkinson’s Disease,” said Rose Wichmann, manager of Struthers Parkinson’s Center in Golden Valley. “It goes to two in 100 people over the age of 70. That’s more than MS, more than muscular dystrophy and more than ALS-Lou Gehrig’s Disease.”

Wichmann was in Fairmont on Thursday speaking to a Parkinson’s support group at Grace Lutheran Church. She mentioned there are several different types of Parkinson’s Disease, and that every person diagnosed has slightly different symptoms.

“Not everyone has the tremors that people associate with Parkinson’s,” Wichmann said. “We have an acronym called ‘TRAP’ that lists the four main symptoms, and two or more of these need to be confirmed before receiving a diagnosis.”

While tremors are well-associated with Parkinson’s, other symptoms are less noticeable, such as rigidity and stiffness in the muscles. There is also the absence or slowing of movements, and posture changes, such as curling over instead of sitting or standing up straight.

“There are about 15 percent of those diagnosed with Parkinson’s that never have a tremor,” Wichmann said. “But what causes Parkinson’s is a group of cells at the base of the brain that produce dopamine. As we age, those cells start to disappear, and about 60 to 80 percent of those disappear before displaying symptoms of Parkinsons.”

Dopamine is a chemical that allows the delivery of messages through the brain. Lack of dopamine means signals are not moving as smoothly.

“We say that automatic is broken,” Wichmann said. “Those movements you don’t even think about, like walking, or rolling over in your sleep. Blinking also goes away, so Parkinson’s sufferers have more of a stare. There is a loss of facial expressions because you don’t think about if you’re going to smile. It’s easy for Parkinson’s people to be misunderstood because you can’t read their facial expressions anymore.”

There are also problems with balance.

The rest is here:
Speaker offers insights into Parkinson's

Source:
http://www.longevitymedicine.tv/feed/

Importance Of Exercise In Health Plans Upheld By Supreme Court Decision

Editor's Choice Main Category: Sports Medicine / Fitness Article Date: 03 Jul 2012 - 8:00 PDT

Current ratings for: Importance Of Exercise In Health Plans Upheld By Supreme Court Decision

Janet Walberg Rankin, Ph.D., ACSM president and an associate dean at Virginia Tech, quoted a US Department of Health and Human Services announcement that physical inactivity will have caused about 7 million premature deaths in the country just in this decade.

Healthy lifestyles, including exercise and physical activity, need to be part of the healthcare equation. Physical activity has been proven to help prevent over 40 chronic conditions and diseases, including diabetes, stroke and heart disease.

Past president of ACSM, Robert Sallis, M.D., FACSM, stressed that having exercise in the health care equation is sound science, and an economic necessity.

Sallis also chairs the Exercise is Medicine global health care initiative that strives to make physical activity and exercise a part in helping prevent disease and treat medical conditions. One of their main goals is to show people that exercise is indeed medicine. The initiative hopes to make physical activity a concern in all health care visits, while leading to policy changes in both public and private settings for physical activity counseling and referrals in clinical settings.

According to the ACSM, 75% of America's healthcare spending goes on treating chronic diseases. Getting patients general physically active does not only help improve treatment outcomes, but can also be a powerful preventive weapon.

Sallis said:

Walberg Rankin and Sallis claim that people of all ages and health status who can become physically active and are able to exercise, are going to gain and maintain better wellness. They believe this should be a main concern in any debate on health policy.

Business already know about this, they added - local and national governments around the world are starting to become aware that there is an enormous impact on the bottom line if people are kept healthy. Between $233 and $381 billion are spent dealing with preventable diseases which would not now be affecting people if they were physically active.

Go here to see the original:
Importance Of Exercise In Health Plans Upheld By Supreme Court Decision

Research and Markets: Handbook of Parkinson’s Disease – Blue-Ribbon Guide

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/lb6wfj/handbook_of_parkin) has announced the addition of the “Handbook of Parkinson’s Disease” book to their offering.

This blue-ribbon guide has long prevailed as one of the leading resources on Parkinson’s Disease (PD). Fully updated with practical and engaging chapters on pathology, neurochemistry, etiology, and breakthrough research, this source spans every essential topic related to the identification, assessment, and treatment of PD. Reflecting the many advances that have taken place in the management of PD, this source promotes a multidisciplinary approach to care and supplies new sections on the latest pharmacologic, surgical, and rehabilitative therapies, as well as essential diagnostic, imaging, and nonmotor management strategies for PD.

Key Topics Covered:

Early Iconography of Parkinson’s Disease

Epidemiology of Parkinsonism

Differential Diagnosis of Parkinsonism

Pathophysiology and Clinical Assessment of Parkinsonian Symptoms and Signs

Autonomic Dysfunction and Management

Sleep Dysfunction in Parkinson’s Disease

Originally posted here:
Research and Markets: Handbook of Parkinson's Disease – Blue-Ribbon Guide

Source:
http://www.longevitymedicine.tv/feed/

BUSM researchers identify role of FOXO1 gene in Parkinson’s disease

Public release date: 28-Jun-2012 [ | E-mail | Share ]

Contact: Jenny Eriksen Leary jenny.eriksen@bmc.org 617-638-6841 Boston University Medical Center

(Boston) A recent study led by researchers at Boston University School of Medicine (BUSM) revealed that the FOXO1 gene may play an important role in the pathological mechanisms of Parkinson’s disease. These findings are published online in PLoS Genetics, a peer-reviewed open-access journal published by the Public Library of Science.

The study was led by Alexandra Dumitriu, PhD, a postdoctoral associate in the department of neurology at BUSM. Richard Myers, PhD, professor of neurology at BUSM, is the study’s senior author.

According to the Parkinson’s Disease Foundation, 60,000 Americans are diagnosed with Parkinson’s disease each year and approximately one million Americans are currently living with the disease.

Parkinson’s disease is a complex neurodegenerative disorder characterized by a buildup of proteins in nerve cells that lead to their inability to communicate with one another, causing motor function issues, including tremors and slowness in movement, as well as dementia. The substantia nigra is an area of the midbrain that helps control movement, and previous research has shown that this area of the brain loses neurons as Parkinson’s disease progresses.

The researchers analyzed gene expression differences in brain tissue between 27 samples with known Parkinson’s disease and 26 samples from neurologically healthy controls. This data set represents the largest number of brain samples used in a whole-genome expression study of Parkinson’s disease to date. The novel aspect of this study is represented by the researchers’ emphasis on removing possible sources of variation by minimizing the differences among samples. They used only male brain tissue samples that showed no significant marks of Alzheimer’s disease pathology, one of the frequently co-occurring neurological diseases in Parkinson’s disease patients. The samples also had similar tissue quality and were from the brain’s prefrontal cortex, one of the less studied areas for the disease. The prefrontal cortex does not show neuronal death to the same extent as the substantia nigra, although it displays molecular and pathological modifications during the disease process, while also being responsible for the dementia present in a large proportion of Parkinson’s disease patients.

Results of the expression experiment showed that the gene FOXO1 had increased expression in the brain tissue samples with known Parkinson’s disease. FOXO1 is a transcriptional regulator that can modify the expression of other genes. Further examination of the FOXO1 gene showed that two single-nucleotide polymorphisms (SNPs), or DNA sequence variations, were significantly associated with age at onset of Parkinson’s disease.

“Our hypothesis is that FOXO1 acts in a protective manner by activating genes and pathways that fight the neurodegeneration processes,” said Dumitriu. “If this is correct, there could be potential to explore FOXO1 as a therapeutic drug target for Parkinson’s disease.”

###

Excerpt from:
BUSM researchers identify role of FOXO1 gene in Parkinson's disease

Source:
http://www.longevitymedicine.tv/feed/

Cancer Risk Lower In Multiple Sclerosis Patients

Editor’s Choice Main Category: Cancer / Oncology Also Included In: Colorectal Cancer;Multiple Sclerosis Article Date: 28 Jun 2012 – 9:00 PDT

Current ratings for: Cancer Risk Lower In Multiple Sclerosis Patients

3 (2 votes)

The study, conducted by researchers at the University of British Columbia and Vancouver Coastal Health, is published in the journal Brain.

Lead author of the study Elaine Kingwell, a postdoctoral fellow in the UBC Faculty of Medicine and Brain Research Center at UBC and VCH Research Institute, explained:

After comparing diagnoses of cancer in MS patients in British Columbia with those of the general public, the researchers discovered that MS patients were less likely to develop cancer. In particular MS patients had a lower risk of developing colorectal cancer. However, the team found that these patients had a slightly increased risk of developing brain and bladder cancer, although this increase was not significant. Furthermore, the risk for non-melanoma skin cancer was significantly higher among patients with relapsing-onset MS.

The researchers note that further studies are required in order to understand why MS patients have a reduced overall risk of developing cancer.

The researchers also found that MS patients who developed cancer usually had larger tumors at time of diagnosis. They state that more researcher is needed to find out why some tumors might be caught later in individuals with MS.

Helen Tremlett, associate professor in the UBC Faculty of Medicine, said: “Because the symptoms of MS can be broad and include feelings of fatigue, it’s possible the symptoms of cancer are being masked or overlooked.”

Tremlett states that MS patients and their physicians should continue to follow cancer screening guidelines, regardless of the study findings. A follow-up study is planned in order for the researchers to determine if cancer mortality rates are altered in MS patients.

Read more here:
Cancer Risk Lower In Multiple Sclerosis Patients

Source:
http://www.longevitymedicine.tv/feed/

New approach to reverse multiple sclerosis in mice models

ScienceDaily (June 28, 2012) Mayo Clinic researchers have successfully used smaller, folded DNA molecules to stimulate regeneration and repair of nerve coatings in mice that mimic multiple sclerosis (MS). They say the finding, published June 28 in the journal PLoS ONE, suggests new possible therapies for MS patients.

“The problem has been to find a way to encourage the nervous system to regenerate its own myelin (the coating on the nerves) so nerve cells can recover from an MS attack,” says L. James Maher III, Ph.D., Mayo Clinic biochemist and senior author on the paper. “We show here that these small molecules, called aptamers, can stimulate repair in the mice we are studying.”

More than 200,000 people have multiple sclerosis. There is no cure and no effective therapy to stop progression or repair damage to the myelin sheath that surrounds and protects the nerves. Without that protection, nerve fibers will be damaged, leading to declining mobility and cognitive function, and other debilitating complications.

MS researchers, including Mayo neurologist Moses Rodriguez, M.D., a co-author on this paper, have focused on monoclonal antibodies in mice to stimulate myelin repair. The Rodriguez and Maher teams, working together, have determined that the aptamers are not only effective, but they are easy and cheap to synthesize — an important point for drug developers. They also are stable and not likely to cause an immune response. This new approach must be validated in other mouse models to see if it might be a candidate for human clinical trials.

The monoclonal antibodies used in earlier research are large and complex, but were shown to promote both cell signaling and remyelination of central nervous system lesions in mice. The aptamers used in this study are less than one-tenth the size of antibodies and are single-strands of DNA containing only 40 nucleotide units.

The research was supported by Mayo Clinic and the National Multiple Sclerosis Society. Co-authors include Branislav Nastasijevic, Brent Wright, Ph.D., John Smestad, and Arthur Warrington, Ph.D., all of Mayo Clinic.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Mayo Clinic.

Here is the original post:
New approach to reverse multiple sclerosis in mice models

Source:
http://www.longevitymedicine.tv/feed/

Mayo Clinic Uses New Approach To Reverse Multiple Sclerosis In Mice Models

Mayo Clinic researchers have successfully used smaller, folded DNA molecules to stimulate regeneration and repair of nerve coatings in mice that mimic multiple sclerosis (MS). They say the finding, published today in the journal PLoS ONE, suggests new possible therapies for MS patients.

“The problem has been to find a way to encourage the nervous system to regenerate its own myelin (the coating on the nerves) so nerve cells can recover from an MS attack,” says L. James Maher III, Ph.D., Mayo Clinic biochemist and senior author on the paper. “We show here that these small molecules, called aptamers, can stimulate repair in the mice we are studying.”

More than 200,000 people have multiple sclerosis. There is no cure and no effective therapy to stop progression or repair damage to the myelin sheath that surrounds and protects the nerves. Without that protection, nerve fibers will be damaged, leading to declining mobility and cognitive function, and other debilitating complications.

MS researchers, including Mayo neurologist Moses Rodriguez, M.D., a co-author on this paper, have focused on monoclonal antibodies in mice to stimulate myelin repair. The Rodriguez and Maher teams, working together, have determined that the aptamers are not only effective, but they are easy and cheap to synthesize an important point for drug developers. They also are stable and not likely to cause an immune response. This new approach must be validated in other mouse models to see if it might be a candidate for human clinical trials.

The monoclonal antibodies used in earlier research are large and complex, but were shown to promote both cell signaling and remyelination of central nervous system lesions in mice. The aptamers used in this study are less than one-tenth the size of antibodies and are single-strands of DNA containing only 40 nucleotide units.

The research was supported by Mayo Clinic and the National Multiple Sclerosis Society. Co-authors include Branislav Nastasijevic, Brent Wright, Ph.D., John Smestad, and Arthur Warrington, Ph.D., all of Mayo Clinic.

SOURCE: Mayo Clinic

Originally posted here:
Mayo Clinic Uses New Approach To Reverse Multiple Sclerosis In Mice Models

Source:
http://www.longevitymedicine.tv/feed/

ABC News Profiles BalanceWear® and the Benefits for Multiple Sclerosis Patients

SAN FRANCISCO–(BUSINESS WIRE)–

Wow, Its like looking at a miracle, isnt it, said Cheryl Jennings, co-anchor of ABC 7 News. She was referring to reporter Carolyn Johnsons Health & Science segment on BalanceWear, a semi-custom made orthotic that has helped dramatically improve stability in patients with MS, Parkinsons disease, stroke, TBI, ataxia and other Sensory Based Motor Disorders (SBMD).

View Full Story Online

For patients suffering from multiple sclerosis or other degenerative diseases, just controlling their own bodies can be a challenge. But now, a simple device invented in the Bay Area is helping a growing number of those patients move far more smoothly, Johnson says as she introduces viewers to Mary Spencer, a woman who suffers with balance issues caused by Multiple Sclerosis and to physical therapist Cindy Gibson-Horn, creator of BalanceWear.

“You can’t tell what direction is what. Your body doesn’t know what’s up or down,” says Mary.

Directional loss is a symptom of several Sensory Based Motor Disorders. As the patient walks, he or she becomes preoccupied with their movements, trying to compensate with every step in order to keep from falling. Gibson-Horn discovered that small, strategically placed weights applied to BalanceWear helps to adjust directional loss. Her research led to the discovery of Balance-Based Torso Weighting (BBTW), a breakthrough that has been noticed by doctors and researchers. Recently, a National Institutes of Health Recovery Grant of just under $400,000 was awarded to Samuel Merritt University (SMU) Physical Therapy Professor Dr. Gail Widener, PT, and Dr. Diane Allen at San Francisco State University to continue research into Balance-Based Torso Weighting (BBTW) and its effects on Multiple Sclerosis (MS) mobility challenges. The first phase of the study validates previous research funded by the National MS Society. The research is currently in its second phase and has led to documented evidence of the efficacy of prior clinical observations.

“If you think about balance, it’s the foundation of movement. So you couldn’t even sit, unless you had balance,” Gibson-Horn tells Johnson. “If the patient has a balance problem, and we can identify the directional losses of balance, then we can treat those imbalances by strategically placing light weights in BalanceWear and immediately you’ll know whether or not your patient is going to experience balance improvement.”

Steve Cookston, CEO of Motion Therapeutics, the company that manufactures and markets BalanceWear, has spent years in the medical device field. BalanceWear has the remarkable ability to change a persons life by simply being fitted for the vest, says Cookston. It requires no downtime, drugs or special care. It is designed and manufactured to insure that the patients balance is dramatically improved immediately and that is what makes us all enthusiastically committed to this product.

Says Johnson, For Spencer, the results have already been life changing.

“I have the freedom to move without thinking, ‘Where do I need to be? How do I need to stand?’” Spencer explains.

Read more here:
ABC News Profiles BalanceWear® and the Benefits for Multiple Sclerosis Patients

Source:
http://www.longevitymedicine.tv/feed/

Dementia has robbed me of my freedom, says Thunderbirds creator Gerry Anderson

He said he did not even know his mental condition was deteriorating and described how the diagnosis came as a shock.

I dont think I realised at all, he told BBC Berkshire.

I don’t think I realised at all. It was my wife Mary who began to notice that I would do something quite daft like putting the kettle in the sink and waiting for it to boil.

“Finally I was persuaded to go and see the doctor and eventually I was confronted with the traditional test – a piece of paper with drawings on it, taking a pencil and copying them.

“I thought ‘Why are they doing this? A child could do this’.

“But when I started to copy the drawings, that wasn’t the case.

“I started to get in a muddle. That’s when I began to realise that there was something wrong.”

He said not being able to drive anymore was the bitterest blow of all because he could not get to Pinewood from his home in Henley-on-Thames.

This depressed me enormously because my film work was my life.

Suddenly my life was cut off. Since I’ve had Alzheimer’s I’ve realised how debilitating it is. It can affect your life in so many ways that you don’t think about, he said.

See the original post:
Dementia has robbed me of my freedom, says Thunderbirds creator Gerry Anderson

Source:
http://www.longevitymedicine.tv/feed/

Dementia: Not a normal part of aging

By GARY LEBLANC | Common Sense Caregiving Published: June 28, 2012 Updated: June 28, 2012 – 12:00 AM

I recently had a conversation with a fellow caregiver that is caring for his elderly mother who is suffering from some type of dementia. He told me that her primary physician diagnosed her with “Old Brain.” I almost fell out of my chair. What kind of medical diagnosis is that?

Dementia is not a normal part of aging. For example, my own mother is 93 years old and as sharp as a whip! I believe this is the way we are all meant to live out our golden years.

If our loved ones show signs of dementia, something is causing it and if their doctors aren’t going to investigate it, I suggest we take them to a neurologist right away. In the case of Alzheimer’s Disease, it’s the disease that has brought on the symptoms of dementia. (Yes. Dementia is a symptom.)

A good analogy to use when explaining the term dementia is “fever.” Fever refers to an elevated temperature, indicating that the person is sick, but it does not explain what is causing the sickness. So, simply stated, dementia is not a disease; it is one of the symptoms of a disease.

Lewy Body Dementia, Parkinson’s Disease, Huntington’s Disease I could go on and on, but in all cases it’s the diseases themselves that have created the symptom of dementia.

The goal of any truly caring doctor is to discover what is causing it, and the sooner the better. There are even some cases such as Vascular Dementia which can be reversed if caught early enough.

Around the age of 60, everyone starts to develop a little brain shrinkage. This may cause some absent mindedness, but this should not necessarily be mistaken for dementia.

Here are a couple of scenarios to consider; we all misplace our keys once in a while, but when we’re holding our car keys in our hand and forget what they are for . . . or if we forget something in our bedroom and we walk back in there and don’t recognize the room we’re standing in, that’s concern for dementia!

If you or your loved one are experiencing this symptom, please see a doctor right away. Now, don’t let the word “Alzheimer’s” be the first thing to pop into your head. There are many probable causes including: vitamin B deficiency, medication side-effects, depression, just to name a few. All avenues should be explored right away.

The rest is here:
Dementia: Not a normal part of aging

Source:
http://www.longevitymedicine.tv/feed/

Grover Beach boy will get service dog thanks to fundraiser; more that 400 attend event

By Mike Hodgson/Associate Editor Email a friend Printer friendly

Lucas Appleton, right, plays with Tony Boy during a fundraiser Sunday at Mangos Saloon in Grover Beach. //Phil Klein/Contributor

A Grover Beach boy stricken with Friedreichs ataxia will get his service dog as a result of a fund-raiser that drew more than 400 people Sunday.

Nine-year-old Lucas Appleton, who suffers from the progressively crippling form of muscular dystrophy, managed to spend five hours at the event at Mongos Saloon, said his godmother, Linda McClure, who organized the barbecue that included a prize drawing, musical performances and a bake sale.

It was a huge success, McClure said. Lucas was so happy and so was his brother (William) and mother, Casandra.

We raised enough to get him a dog, with a small amount left over for a van, and were working on that now, she said.

A trained service dog, which costs $12,000 to $15,000, will help Lucas maintain his balance, turn on lights for him, pick up things hes dropped, help him through the familys narrow bathroom door and just be a companion.

McClure said about 450 people and a host of dogs attended the event that started at 10:30 a.m. and continued until Mongos closed that night.

She noted Lucas had asked to have a golden retriever or black Labrador retriever for a service dog, which might not be possible.

But a golden retriever club heard about his request and showed up with all their dogs.

See the rest here:
Grover Beach boy will get service dog thanks to fundraiser; more that 400 attend event

Source:
http://www.longevitymedicine.tv/feed/

Nighttime leg cramps hurt patient

Dear Dr. DonohueI have leg cramps at night quite often. They wake me up, and I have to straighten my leg slowly. I do 15 bends, squats, modified push-ups and sit-ups every night. What causes these cramps? What can I do to stop them? I am physically fit and healthy at age 80. R.C.

AnswerNighttime leg cramps are the bane of a significant number of older people. What causes them is a question to which no one has come up with an answer. That hasn’t stopped people from suggesting a number of possible causes: low magnesium, low potassium, too little calcium. None of these has been proved.

Some medicines have been implicated as possible causes. Water pills (diuretics) have been cited, as have long-acting beta-2 agonists used for asthma control.

Peripheral artery disease, a common malady of the elderly, is said to be common among people who suffer from nighttime cramps. That’s the circulatory problem where there’s obstruction to blood flow to the legs because of clogged arteries. The various kinds of arthritis also are said to contribute to nighttime cramping.

Ways to end cramps include doing exercises before going to bed. Leg exercise is particularly important. If you have a stationary bike, it might be one way to conquer cramps. Stretching exercises for the leg muscles also are important. If the calves are cramping, then stand on a stair with your heels projecting off the stair. Lower your heels, and hold that position for 10 seconds. Repeat 10 times at bedtime, and do this exercise three times during the day.

Medicines sometimes can be helpful if nothing else is working. Examples are gabapentin (Neurontin), diltiazem (Cardizem) and a multivitamin containing a mix of B vitamins. Tonic water, because of its quinine content, often is offered as a preventive step.

The booklet on restless leg syndrome and nighttime cramps offers more tips. Readers can obtain a copy by writing: Dr. Donohue No. 306, Box 536475, Orlando, FL 32853-6475. Enclose a check or money order (no cash) for $4.75 with the recipient’s printed name and address. Please allow four weeks for delivery.

Dear Dr. DonohueMy husband was diagnosed with ataxia. What is it? R.A.

AnswerAtaxia is uncoordinated muscle movement. For most ataxia patients, it indicates a stumbling walk.

Follow this link:
Nighttime leg cramps hurt patient

Source:
http://www.longevitymedicine.tv/feed/

Autism Surge Due To Diagnostic Changes, Analysis Finds

}roF3e3LJE”9iY3g1v_od/XI}eFn4_pK6&.xUzS^`5X/ +/UXeEQ>NkvG{ffGv:8Ysl’7mqyd4 F~Mb#aOs3pyYq/:]Nb /m~.k7 6Qq>fN>2: LD.#&#.bn|v#c1=vL8r;ZY3P$6a|v~H.yg&Bqh:682}~uLcxzQuspjC~G>s&=d7ulWf&1HN{pr+r|o’wuLvQcWf=~1V L`ce={‘kf]^#hVnZfF$7Sxvn!0- 4_zPA( L8b`0dJsEUsqj4[U fX8Wfh[sVAAA.n@V?f_pO<ETv’EsIWZ&j0z !ej2>NOL5,-F5pSOYOZUm*gtrG0^1gO4cQ+~l3W]4+J kf5c6$~y8S~g$DX=0~@D =U0B9u25`[:tk=,(m @teN'u)u%<P# wF8ff*)x{Y}z9+#=lL}a1u<?28l.s @yO|.pFAko3@9*+/D2Ob{D9ZuL6C3.t~BG4+H%f; haBm"'O1Hl!k+ IJ]vEkZCd,G#=t[Ch Pl^cG*q44:hg % GCIcWb8,?"Sy7Z/I6G}L8.s{0[1,K5a`@LC0jQ)f 9@FUvJRB?-e/YBev.Uks ff#5q61G`JZ=wFHvwvNr DZ9~LVg_lOpjvPzFFjvwZFyVa%.AQD~k?M~=Vy/}% fh_sr~ px4~ccvV7 |{Z*S D<W2t9nf(i&3TOP/zD~b3d;X^f7FC6Y9'@q-jkF$efXv* @71=|3C*tC-lP7d$]_xVfxmx 4SM #:n$(TJ>}n:d||b[sQ=+sIx5mU]GxoW3Y !p`OZT@5]WRkT5[lve]8W@_cCcjJ M|6ar?Lf[+u5hQ fx]_oaI[5 B-Hd 0 8ssPsvRQ{}jUAUt?5 ?0]`QE=90?f3#Uf#?N”w**”LGu]T}E?5CdDSPvr]C[bQq ep[-]“aBow|hfF[}3<_!CI68l'fke5=BS =5.Xe?Uhv"bR]r ZdrPf{5^}HCq<dD Dh=c1;SIdzB3AJ+A104..OpxOFcBW0o3E{0Acs[]KaZn@G,R&,(P Cb=c!.kI^kt5X#Yt4s1s8/+d= B0-6R)%.c4 9*`wLB:F#}T8 F B[Yr!(xYJ YGYHHgd=n!RzW{ 78l"MNEhaR]lM2:=D&uAivVxXr” IX/nH*3V’9RSrRD],?dS 7ocg_5vlbsk&}g1l7;Nqt?#:x0fQHc’mm['GG<S$pLG#$SF08+c[d83Cur/lfBF, OK<rghO;D$je}$B]FVf]Af]hvq|CN;@70vo)DupIP7)Gj.XBzWI#!L3r4FrB#6 Q$UQO+g/FG}~BO,)!z^do,B1#&PTBa@/h/N!*p@0VF,4J.!ecs9Cz JxX!n?KxU2b}Y3@vh8g-TUJhP3@}n)##3rZi4UW2tpJW^>}GZUO3J wq2pblpfwB1(yL[6K&=FaqHU~ieJZ`u-"`s?l$.B5v-G&Y1k408unBaVkA}x6ISCCf=G=G J&*~;A?M|Azp!9h80nqzHb=kaupPD.7p86#5]-`)j”[-R9;#c9&X@Equu#p:cpHWj+""b4aHuJ0 lJ[I3La(LGCIH-69xhM!0r^@Yg8CttKIi)iB;N`dQ ~0x YK+r1x:}H6(L}Ocdnh]/mf 8TdTMhFCxU2hu!;$EiSw841z8l uNIdn{]_@’@ xroKF#8O!-4I%[t= (uni >QSo$I:f/0:$r t6 |'grI(R,>8iy?Kpn ,+KJ.BXIq-SYO`S6Td$tp<LqQHx~ Et,Vf#xMr:M2HPb!2,%@;a{I~3:-2t="sL.b.wATXOCC_7 |hUN*)JRI @ZUqY.]UeU]U B$Nub^1%F-*vg@HP]P5D,SOA’yO b’UhCHdx ‘jd<i3p/y{rf8ENk]sl}Xv8:gzN* T}1 eOL/^ZU][H*[7V~!'&+C.|cyV^q[U'}4/^SGWFfi^kje)E_Sd.8Yy(;-<D]oDG;k=#3VdX s?b+;T50YItgx7'KHu:dpr+RRK)GJQE/c1rATv%GtqDAStV0E{%S(k dQ%;#WC]Hlyc+"Gy%7Kg8IvF;VH37aWd CFTG~}c5dW<.7#SXIc t((<'981o%i{1sV:H42etPDb?{xY^7;&hy kW8xNy:2Zn)’9z~V&)OmH5a{m/I&Sf~0`*KCLm{_O5x:Jn`U”IC[&-&q|RBm65_7A-i`|{,D6^e`-3ikS)g&N4 c^j ;`?ld)$kJ ]~I7@8}V6LHB/7;IMx2 gdT5ZN{1C8^V>&i.MMgIsak IVFNpT#a3VsCQ j0 5)$)nY){ ?7%N2HUkiZdKh=:^S}n4g{eJj’vr5R] ?GtC/;kb9.+|58p)1H ?`bl={2 9LmPc YJ: z9M’bzr4R;4]$?_2^f7bYPe(.~9Q6^>@?4GXBN5-f]2^4:{I2o}6(}73da.3|+O|,8Hr5+{wv^z@ gf**MwJD[SlX'Nk~i0*bf+S(lMQZ#g4@?[If0i7i4:g}(9/N+SHe@z9gd"w2`??1ZplHAHnE.%x Hm8 W=?$ Z@(glIZWJ^ 3'0O[KY&$HB4Y7g!oW..S<&3`G3s+S)GIU2S((6L&8B4/8K?Mu.8*#N9[RTB9ce!sCPAM/bw+?P.!^N4YfdJK6*"XYR|A~tD//I6]D>(j1??4AfurQV<] U}=1r!(@.opX#}kx|06S1M'_ey^mVD'v??FO+Cx]:3qzGQu vNetf

See the article here:
Autism Surge Due To Diagnostic Changes, Analysis Finds

Source:
http://www.longevitymedicine.tv/feed/

Brain scans may detect autism in babies and toddlers

One study examines the brain’s organization of white matter, while another measures its electrical activity — in both cases, to detect autism.

Two separate studies published this month indicate that it may be possible to use brain imaging techniques to reliably detect autism in children as young as 6 months of age.

In the first study, published in the American Journal of Psychiatry, researchers from across North America working on the larger and ongoing Infant Brain Imaging Study used a type of MRI called diffusion tensor imaging to study 92 6-month-olds deemed high risk because their older siblings had been diagnosed with autism.

What they found is that the organization of white matter in the brain plays a key role. Specifically, they looked at fractional anisotropy (FA), which in this case measured white matter organization using the movement of water through tissue. They found that FA values were higher in 6-month-old infants who went on to develop autism, but then underwent a dramatic drop over the ensuing months and were ultimately lower than the values of those without autism when measured again at 2 years of age.

“Infancy is a time when the brain is being organized and connections are developing rapidly,” Dr. Alan Evans, co-investigator out of McGill University in Montreal, said in a news release. “Our international research team was able to detect differences in the wiring by six months of age in those children who went on to develop autism.”

Meanwhile, a larger study published in the journal BMC Medicine investigated patterns of electrical activity in the brains of almost 1,000 children between the ages of 2 and 12. Using electroencephalograms (EEGs) consisting of caps of 24 electrodes, researchers identified 33 patterns they say can reliably distinguish children who have autism from those who do not.

The majority of the 33 patterns revealed decreased brain activity — particularly on the left side of the brain, which is responsible for communication — but roughly a third of the patterns showed increased activity.

“They may be the brain’s attempt to overcompensate for the regions that should be working together,” Frank Duffy, a developmental neurophysiologist at Boston Children’s Hospital and an associate professor at Harvard Medical School, told WebMD. “There’s also a high association of autism with seizure disorders. An over-connected brain may be more prone to seizures than an under-connected brain.”

Researchers from both studies say they hope their methods and findings will pave the way to the very early detection of autism, as early intervention could in turn help improve children’s outcomes later in life.

View original post here:
Brain scans may detect autism in babies and toddlers

Source:
http://www.longevitymedicine.tv/feed/

Boy will get service dog thanks to fundraiser

By Mike Hodgson/Associate Editor Email this story Print this story

Lucas Appleton, right, plays with Tony Boy during a fundraiser Sunday at Mangos Saloon in Grover Beach. //Phil Klein/Contributor

A Grover Beach boy stricken with Friedreichs ataxia will get his service dog as a result of a fund-raiser that drew more than 400 people Sunday.

Nine-year-old Lucas Appleton, who suffers from the progressively crippling form of muscular dystrophy, managed to spend five hours at the event at Mongos Saloon, said his godmother, Linda McClure, who organized the barbecue that included a prize drawing, musical performances and a bake sale.

It was a huge success, McClure said. Lucas was so happy and so was his brother (William) and mother, Casandra.

We raised enough to get him a dog, with a small amount left over for a van, and were working on that now, she said.

A trained service dog, which costs $12,000 to $15,000, will help Lucas maintain his balance, turn on lights for him, pick up things hes dropped, help him through the familys narrow bathroom door and just be a companion.

McClure said about 450 people and a host of dogs attended the event that started at 10:30 a.m. and continued until Mongos closed that night.

She noted Lucas had asked to have a golden retriever or black Labrador retriever for a service dog, which might not be possible.

But a golden retriever club heard about his request and showed up with all their dogs.

Read the original post:
Boy will get service dog thanks to fundraiser

Source:
http://www.longevitymedicine.tv/feed/